AAAAAA

   
Results: 1-9 |
Results: 9
HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY
Authors: MERROUCHE Y EXTRA JM ABIGERGES D BUGAT R CATIMEL G SUC E MARTY M HERAIT P MAHJOUBI M ARMAND JP
Citation: Y. Merrouche et al., HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY, Journal of clinical oncology, 15(3), 1997, pp. 1080-1086
PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS
Authors: ABIGERGES D ARMAND JP CHABOT GG BRUNO R BISSERY MC BAYSSAS M KLINKALAKL M CLAVEL M CATIMEL G
Citation: D. Abigerges et al., PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS, Anti-cancer drugs, 7(2), 1996, pp. 166-174
RATIONALE FOR THE DOSAGE AND SCHEDULE OF CPT-11 (IRINOTECAN) SELECTEDFOR PHASE-II STUDIES, AS DETERMINED BY EUROPEAN PHASE-I STUDIES
Authors: ARMAND JP EXTRA YM CATIMEL G ABIGERGES D MARTY M CLAVEL M
Citation: Jp. Armand et al., RATIONALE FOR THE DOSAGE AND SCHEDULE OF CPT-11 (IRINOTECAN) SELECTEDFOR PHASE-II STUDIES, AS DETERMINED BY EUROPEAN PHASE-I STUDIES, Annals of oncology, 7(8), 1996, pp. 837-842
ETOPOSIDE BIOAVAILABILITY AFTER ORAL-ADMINISTRATION OF THE PRODRUG ETOPOSIDE PHOSPHATE IN CANCER-PATIENTS DURING A PHASE-I STUDY
Authors: CHABOT GG ARMAND JP TERRET C DEFORNI M ABIGERGES D WINOGRAD B IGWEMEZIE L SCHACTER L KAUL S ROPERS J BONNAY M
Citation: Gg. Chabot et al., ETOPOSIDE BIOAVAILABILITY AFTER ORAL-ADMINISTRATION OF THE PRODRUG ETOPOSIDE PHOSPHATE IN CANCER-PATIENTS DURING A PHASE-I STUDY, Journal of clinical oncology, 14(7), 1996, pp. 2020-2030
CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER
Authors: ARMAND JP DUCREUX M MAHJOUBI M ABIGERGES D BUGAT R CHABOT G HERAIT P DEFORNI M ROUGIER P
Citation: Jp. Armand et al., CPT-II (IRINOTECAN) IN THE TREATMENT OF COLORECTAL-CANCER, European journal of cancer, 31A(7-8), 1995, pp. 1283-1287
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS
Authors: CHABOT GG ABIGERGES D CATIMEL G CULINE S DEFORNI R EXTRA JM MAHJOUBI H HERAIT P ARMAND JP BUGAT R CLAVEL M MARTY ME
Citation: Gg. Chabot et al., POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS, Annals of oncology, 6(2), 1995, pp. 141-151
A NEW ENKEPHALINASE INHIBITOR AS AN ALTERNATIVE TO LOPERAMIDE IN THE PREVENTION OF DIARRHEA INDUCED BY CPT-11
Authors: GONCALVES E DACOSTA L ABIGERGES D ARMAND JP
Citation: E. Goncalves et al., A NEW ENKEPHALINASE INHIBITOR AS AN ALTERNATIVE TO LOPERAMIDE IN THE PREVENTION OF DIARRHEA INDUCED BY CPT-11, Journal of clinical oncology, 13(8), 1995, pp. 2144-2146
PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS
Authors: ABIGERGES D CHABOT GG ARMAND JP HERAIT P GOUYETTE A GANDIA D
Citation: D. Abigerges et al., PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS, Journal of clinical oncology, 13(1), 1995, pp. 210-221
IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA
Authors: ABIGERGES D ARMAND JP CHABOT GG DACOSTA L FADEL E COTE C HERAIT P GANDIA D
Citation: D. Abigerges et al., IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA, Journal of the National Cancer Institute, 86(6), 1994, pp. 446-449
Risultati: 1-9 |